Loading clinical trials...
Loading clinical trials...
The Expression of TLR2 and TLR4 in the Lung of COPD Patients
Smoking is the most important risk factor of COPD, but only a fourth of smokers had COPD in their life. There are also healthy smokers without evidence of COPD. Investigators hypothesize that innate immunity may affect this difference between COPD patients and healthy smokers, because TLR4 is the receptor of LPS, which is the one of important substance in cigarette. Investigators will measure TLR2 and TLR4 expression in lung tissue of patients whose lung will be resected. Investigators will compare the level of expression between COPD patients and healthy smokers.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Seoul National University Bundang Hospital
Seongnam, Gyeongi, South Korea
Start Date
October 1, 2010
Primary Completion Date
December 1, 2011
Completion Date
March 1, 2012
Last Updated
June 8, 2011
60
ESTIMATED participants
Lead Sponsor
Seoul National University Bundang Hospital
NCT07477600
NCT06372899
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07462221